佳礼资讯网

 找回密码
 注册

ADVERTISEMENT

查看: 31261|回复: 561

CTIC 第二贴。

[复制链接]
发表于 16-6-2009 06:45 PM | 显示全部楼层 |阅读模式
太卡了,所以开第二贴,希望之前的LZ不会骂我吧。
回复

使用道具 举报


ADVERTISEMENT

发表于 16-6-2009 07:44 PM | 显示全部楼层
http://finance.yahoo.com/news/Pi ... -15532701.html?.v=1

Pixantrone Overview in Non-Hodgkin's Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference
On Tuesday June 16, 2009, 1:30 am EDT
       Buzz up!
SEATTLE, June 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of Ottawa Hospital will be presenting an overview of pixantrone clinical studies in non-Hodgkin's lymphoma at the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be held from June 22-26, 2009 at the Fairmont Orchid hotel on the Big Island of Hawaii.


看来这个星期五股价应该会上。。
回复

使用道具 举报

 楼主| 发表于 16-6-2009 09:49 PM | 显示全部楼层
在这拜五,你要下完身家吗?
回复

使用道具 举报

发表于 16-6-2009 10:17 PM | 显示全部楼层
原帖由 软趴趴 于 16-6-2009 09:49 PM 发表
在这拜五,你要下完身家吗?

应该不会吧。。
至少要留一点后路给自己。。
回复

使用道具 举报

 楼主| 发表于 17-6-2009 12:29 AM | 显示全部楼层
The other complicating issue is the declining volume of Cell Therapeutics' shares trading hands each day. This makes it harder for bondholders to liquidate the stock they receive in the exchange offer.

Trading volume in Cell Therapeutics shares on June 2 was more than 77 million shares, but it dropped to as low as 13 million shares on June 10 and was only 37 million shares Monday.
At Monday's stock price, Cell Therapeutics would be issuing slightly fewer than 50 million shares to bondholders.  If Cell Therapeutics is successful with its debt tender offer, the company still has money problems to solve. The company's cash reserve is set to run dry in August, according to a recent filing with the Securities and Exchange Commission. Cell Therapeutics has taken further cost-cutting steps to make its cash last longer, but that didn't prevent management from accepting deferred cash bonuses from 2008 last week. Cell Therapeutics will need to raise more cash -- perhaps by selling even more stock -- if it wants to continue the development of its cancer drug pixantrone, among other projects. The company already has more than 452 million shares outstanding as of the end of April.

不什么会看英文 ,好像是欠人很多钱吧。
很想不稳哦。
是不是说八月他们的钱会用完??
回复

使用道具 举报

发表于 17-6-2009 01:26 AM | 显示全部楼层
同一个人。。。
ADAM....

他是著名 CTIC 的 BASHER...
不过  CTIC的确 欠人钱。。。所以之前才回沦落到 差一点 被 DELISTED..

乱爬爬,你的  GM   卖了吗?

[ 本帖最后由 jochen 于 17-6-2009 02:21 AM 编辑 ]
回复

使用道具 举报

Follow Us
发表于 17-6-2009 02:18 AM | 显示全部楼层
http://finance.google.com/group/ ... ad/da6bf2cb8b2c6d22

长期跟着CTIC 。。。

都知道CTIC 有财务问题。。。基本上, 他的本钱
就是  2个  phase 3 的 药 pixantrone....&  opaxio(xyotax)
回复

使用道具 举报

发表于 17-6-2009 10:06 AM | 显示全部楼层
Tomorrow's Monster Stocks

By Rich Duprey
June 16, 2009

http://www.fool.com/investing/ge ... monster-stocks.aspx

Stocks climbing to 10 times their original price are rare breeds -- but they're not impossible to find. Especially when you have Fools for friends.

The market's best stocks include companies that have risen dozens of times in value over the past decade. These aren't penny stocks; they're viable companies with sound business prospects, achieving phenomenal returns every year. Finding just one or two of these monstrously successful companies can help you establish a winning portfolio.

Stalking the monster
To find tomorrow's winners, we'll enlist the more than 135,000 monster trackers at Motley Fool CAPS. We've compiled a list of the most successful CAPS members, dubbed All-Stars, whose picks include ones that have doubled, tripled, or even quadrupled in price. Then we've plucked out some of their recent picks for stocks they find equally promising.
回复

使用道具 举报


ADVERTISEMENT

 楼主| 发表于 17-6-2009 10:41 AM | 显示全部楼层

回复 6# jochen 的帖子

全部买了。USD1.50
回复

使用道具 举报

发表于 17-6-2009 12:28 PM | 显示全部楼层
它每次都是这样
上一天,就跌回一天
有点后悔那天1.66没有卖它
再买回来也是一样的本钱
回复

使用道具 举报

 楼主| 发表于 17-6-2009 07:07 PM | 显示全部楼层
Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
Cell Therapeutics, Inc. (the "Company" or "CTI" (Nasdaq and MTA: CTIC) today announced the preliminary results of its separate concurrent fixed price exchange offers (each, an "Exchange Offer" and together, the "Exchange Offers" for any and all of the approximately $118.9 million outstanding principal amount of five series of its convertible notes (the "Notes". The Exchange Offers expired at 5:00 p.m., New York City time, on Tuesday, June 16, 2009.

In accordance with the terms and conditions of the Exchange Offers, and based on the preliminary count by U.S. Bank National Association, the depositary for the Exchange Offers, the Company expects to accept for exchange approximately $54.8 million aggregate principal amount of the Notes for the previously announced exchange consideration of (i) $134.50 cash, and (ii) 458 shares of common stock per $1,000 principal amount of Notes validly tendered and not withdrawn in each Exchange Offer, for a total amount of exchange consideration (excluding interest, fees and other expenses in connection with the Exchange Offers) of approximately $7.4 million cash and approximately 25.1 million shares of common stock.
The approximately $54.8 million aggregate principal amount of Notes to be exchanged includes approximately $5.9 million principal amount of Notes tendered by notice of guaranteed delivery.

Noteholders who tendered their Notes by delivering a notice of guaranteed delivery prior to the expiration of the Exchange Offers must deliver the related Notes and required documents to the depositary within three business days of their execution of the notice of guaranteed delivery.

"I am pleased we completed the Exchange Offers with a substantial portion of outstanding Notes tendered and am encouraged by the confidence continuing holders of our Notes have in the prospects of the Company moving forward," said James A. Bianco, M.D., CEO of the Company. "This transaction will significantly clean up our balance sheet, decrease our ongoing expenses with the elimination of approximately $54.8 million of debt, reduce our annual interest expense by approximately $3.4 million, and increase our shareholder's equity. In addition, this transaction should make the Company a more attractive opportunity for biotechnology investors and position us well as we move to complete the submission of our New Drug Application for pixantrone to treat relapsed and refractory, aggressive non-Hodgkin's lymphoma to the U.S. Food and Drug Administration this month."

The Company expects to accept for exchange the following approximate principal amount of each series of Notes:

         (i)  $13,537,000, or 24.6%, of the $55,150,000 aggregate outstanding              principal amount of 4% Convertible Senior Subordinated Notes              due 2010;         (ii)  $12,087,000, or 52.6%, of the $23,000,000 aggregate               outstanding principal amount of 5.75% Convertible Senior Notes               due 2011;        (iii)  $5,500,000, or 78.6%, of the $7,000,000 aggregate outstanding               principal amount of 6.75% Convertible Senior Notes due 2010;         (iv)  $23,358,000, or 69.8%, of the $33,458,000 aggregate               outstanding principal amount of 7.5% Convertible Senior Notes               due 2011; and          (v)  $335,000, or 100.0%, of the $335,000 aggregate outstanding               principal amount of 9.0% Convertible Senior Notes due 2012.
As of June 16, 2009, approximately $118.9 million aggregate principal amount of the Notes was outstanding. Accordingly, the aggregate principal amount of Notes that the Company expects to exchange in the Exchange Offers represents approximately 46.1% of the currently outstanding principal amount of Notes.

Final results for the Exchange Offers will be determined subject to confirmation by the depositary of the proper delivery of Notes validly tendered and not withdrawn and will be announced following the confirmation process.

The Company expects that the settlement date for the Exchange Offers will be Monday, June 22, 2009. Accrued and unpaid interest to, but excluding, the settlement date on Notes accepted for exchange will be paid in cash.

The financial advisor for the Exchange Offers is Piper Jaffray & Co., the information agent for the Exchange Offers is Georgeson Inc. and the depositary for the Exchange Offers is U.S. Bank National Association.

什么是 Exchange Offer??
回复

使用道具 举报

发表于 17-6-2009 07:11 PM | 显示全部楼层

Adam Feuerstein
记住这个家伙的样子
常常都可以看到这个家伙打击ctic和heb
回复

使用道具 举报

 楼主| 发表于 17-6-2009 08:44 PM | 显示全部楼层

回复 12# 白面包 的帖子

可能他要趁低吸购ctic的票吧。
太好价它很难买进。
回复

使用道具 举报

发表于 17-6-2009 10:21 PM | 显示全部楼层
每天跌一点。。
周末的时候可能会释放一点消息在星期一的pre-market升高
把握星期一了
回复

使用道具 举报

发表于 17-6-2009 10:32 PM | 显示全部楼层
原帖由 -=爱相随=- 于 17-6-2009 09:17 PM 发表
Pre-Market: 1.34 -0.21 (-13.55%) -

亏钱了



机会难逢。。。

这是进场的时候!!!!!

什么叫亏钱?。。。没卖就没亏。。。。
回复

使用道具 举报

发表于 17-6-2009 10:55 PM | 显示全部楼层
原帖由 jEMi 于 17-6-2009 10:21 PM 发表
每天跌一点。。
周末的时候可能会释放一点消息在星期一的pre-market升高
把握星期一了

有同感
现在可以观望一下价钱
满意就可以进场了
星期一上了过后再卖掉等机会。。
回复

使用道具 举报


ADVERTISEMENT

发表于 18-6-2009 08:47 PM | 显示全部楼层
今天看来也是冒冷汗
回复

使用道具 举报

发表于 18-6-2009 08:56 PM | 显示全部楼层
可參考下CTIC的CandleStick 圖。

http://americanbulls.com/StockPa ... cker=NASD&TYP=S

Today a  White Candlestick  was formed. This represents normal buying pressure.
回复

使用道具 举报

发表于 18-6-2009 08:58 PM | 显示全部楼层
原帖由 nehooi05 于 18-6-2009 08:47 PM 发表
今天看来也是冒冷汗



要是買進長期的話,
可用先賣後買那招,拿些利息。

買賣自負。
回复

使用道具 举报

发表于 18-6-2009 09:02 PM | 显示全部楼层
wauuu

有钱再收........
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 注册

本版积分规则

 

ADVERTISEMENT


本周最热论坛帖子本周最热论坛帖子

ADVERTISEMENT



ADVERTISEMENT

ADVERTISEMENT


版权所有 © 1996-2023 Cari Internet Sdn Bhd (483575-W)|IPSERVERONE 提供云主机|广告刊登|关于我们|私隐权|免控|投诉|联络|脸书|佳礼资讯网

GMT+8, 23-2-2025 05:11 PM , Processed in 0.106994 second(s), 21 queries , Gzip On.

Powered by Discuz! X3.4

Copyright © 2001-2021, Tencent Cloud.

快速回复 返回顶部 返回列表